DSM announces June opening of new cGMP biopharmaceutical manufacturing
operation in Brisbane, Australia
DSM Pharmaceutical Products, the custom manufacturing and technology business
of Royal DSM (NYSE, Euronext: DSM KON), announced today that their new cGMP
custom biopharmaceutical manufacturing 'biologics plant of the future' will
open in June 2013.
PARSIPPANY, N.J., April 22, 2013
PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- The DSM facility was built
with cooperation from the Queensland and Commonwealth Governments of
Australia. Karen King, President of DSM Biologics, the biopharmaceutical
manufacturing business of DSM Pharmaceutical Products, stated, "We are
thrilled to announce the June opening of ournew cGMP facility in Brisbane.
This operation combines DSM's twenty five years of experience and high quality
track record in mammalian cell culture manufacturing with a state-of-the-art
commercial and development facility. Our partnership with the Government of
Queensland and the Commonwealth of Australia has led to this important
addition to the Australian biotechnology industry and will be a key
contributor to the entire Asia-Pacific region."
(Photo: http://photos.prnewswire.com/prnh/20130422/NY98211 )
Alexander Wessels, President and CEO of DSM Pharmaceutical Products commented,
"We are particularly delighted to be bringing our world-class operating
ability to the Asia-Pacific region, an important growth area in our strategic
development in the biopharmaceutical field; to provide further value to our
customers in this region and around the globe." Australia has a vibrant
biotechnology industry, but previously had no custom mammalian-based
biopharmaceutical manufacturing operation in country. The Queensland
Government formed BioPharmaceuticals Australia (BPA), who has partnered with
DSM to bring this new facility and operation to Brisbane.
David Hughes, CEO of BioPharmaceuticals Australia said, "The opening of this
facility satisfies a national capability gap. Our partnership gives Australia
and the wider region access to DSM's extensive experience, expertise and
ongoing commitment to developing improved bioprocessing technologies. DSM's
operations are a good strategic fit with Australia's existing capabilities and
we are already seeing flow-on benefits from local alliances."
The DSM operation will provide cGMP mammalian cell-culture contract
manufacturing services from process development through to commercial
manufacturing. DSM Biologics operates with all standard technologies and also
has a portfolio of proprietary technologies for the optimization of
biopharmaceutical manufacturing, reducing the cost and risk of mammalian cell
culture. The facility has an output capability of 500kg and has expansion
space available for further capacity utilization.
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
DSM's 23,500 employees deliver annual net sales of around € 9 billion. The
company is listed on NYSE Euronext. More information can be found at
www.dsmbiologics.com and www.dsm.com
For more information:
Guy Tiene Karen King
Director, Marketing and Communications President
DSM Pharmaceutical Products DSM Biologics
tel. +1 973 257 8160; mob. +1 201 650 1667 tel. +1 973 257 8427
email email@example.com email firstname.lastname@example.org
SOURCE DSM Pharmaceutical Products
Press spacebar to pause and continue. Press esc to stop.